Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.

ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

Platelet rich plasma was slightly more effective than no treatment for hair loss in alopecia areata patients.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

Elderly patients frequently suffer from skin conditions, especially inflammatory ones, highlighting the need for better healthcare.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Baricitinib may not always prevent relapse in alopecia areata.

AH-001 could be a safer and more effective treatment for hair loss.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Hispanic and Black patients are underrepresented in alopecia areata clinical trials.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

Alefacept does not effectively treat severe alopecia areata.